Limits...
A new curcuma extract (flexofytol®) in osteoarthritis: results from a belgian real-life experience.

Appelboom T, Maes N, Albert A - Open Rheumatol J (2014)

Bottom Line: Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs.Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months.We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

View Article: PubMed Central - PubMed

Affiliation: University of Brussels, Belgium.

ABSTRACT
This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

No MeSH data available.


Related in: MedlinePlus

Pain reduction was associated with better mobility andquality of life.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4209497&req=5

Figure 1: Pain reduction was associated with better mobility andquality of life.

Mentions: Pain severity progressively and significantly declined in most patients within 6 months; the mean score fell from 6.9 to 3.2 (p<0001; Fig. 1). The patient’s impression of flexibility significantly increased from a mean score of 4.2 prior to treatment to 6.7 after 6 months of therapy (p<0.0001) (Fig. 1). This double improvement was associated with better quality of life, since the mean score increased from 4.7 to 6.9 within the same time period (p<0.0001) (Fig. 1). It is interesting to note that most of the reported improvement occurred within the first 6 weeks of therapy.


A new curcuma extract (flexofytol®) in osteoarthritis: results from a belgian real-life experience.

Appelboom T, Maes N, Albert A - Open Rheumatol J (2014)

Pain reduction was associated with better mobility andquality of life.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4209497&req=5

Figure 1: Pain reduction was associated with better mobility andquality of life.
Mentions: Pain severity progressively and significantly declined in most patients within 6 months; the mean score fell from 6.9 to 3.2 (p<0001; Fig. 1). The patient’s impression of flexibility significantly increased from a mean score of 4.2 prior to treatment to 6.7 after 6 months of therapy (p<0.0001) (Fig. 1). This double improvement was associated with better quality of life, since the mean score increased from 4.7 to 6.9 within the same time period (p<0.0001) (Fig. 1). It is interesting to note that most of the reported improvement occurred within the first 6 weeks of therapy.

Bottom Line: Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs.Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months.We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

View Article: PubMed Central - PubMed

Affiliation: University of Brussels, Belgium.

ABSTRACT
This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

No MeSH data available.


Related in: MedlinePlus